Please login to the form below

Not currently logged in

People, April, 2011

Recent high-profile moves in the pharmaceutical and healthcare industriesMover of the month is Richard Bergström who succeeds Brian Ager as director general of the European Federation of Pharmaceutical Industries and Associations

Mover of the month

 Richard Bergström

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced Richard Bergström succeeds Brian Ager as director general from April 1. Bergström is currently director general of Swedish research-based pharmaceutical industry association LIF. Bergström has almost 20 years of experience in the pharma industry. Before moving to LIF in 2002, he held senior positions in regulatory affairs for both Roche and Novartis in Switzerland. He has been a member of the EFPIA board for a number of years, and chairs its Trust Committee and Task Force on Health Technology Assessment. He is also a council member of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). He has served on several Swedish government commissions and is currently vice chairman of the board of the Karolinska Institutet.

David Barratt has left Euro RSCG Life to set up Healthcare Communications Consultancy, a management consultancy helping agencies and procurement departments

David Barratt

Cecile Paillous  

Cécile Paillous has been selected as vice president of corporate quality at Ethypharm. She also  ecomes a member of the executive committee. Paillous, who joined Ethypharm in 1995, has been given the mission of implementing and developing a consistent and international standard compliant quality system within the Industrial Operations and Scientific Affairs Departments in all Ethypharm's locations.

David Redfern has been chosen as the chairman of the board for ViiV Healthcare, the global specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer, following the retirement of Julian Heslop. Redfern will continue to serve as chief strategy officer at GSK, which owns a majority share in ViiV Healthcare.

 David Redfern

Dr Elliot Sigal

Dr Elliott Sigal has been elected to the board of directors at Bristol-Myers Squibb. He will also become a member of the board's science and technology committee. Sigal is executive vice president, chief scientific officer and president, Bristol-Myers Squibb Research and Development, a position he has held since 2004. He joined the company in November 1997 as vice president of applied genomics.

TxCell has appointed Dr François Meyer as chief executive. Meyer has more than 25 years of pharmaceutical and biotechnology experience, working at Ciba-Geigy Pharma, Sandoz Pharma, Rhone Poulenc Rorer, Aventis Pharma and Centelion.

Francois Meyer



DDB Health - Martin HafleyDDB Health team

DDB Health has promoted senior art director Martin Hafley to head of art. Hafley has been with DDBH for four years. The company has announced the promotion of three account executives to senior account executives. DDB Health said the trio of Isla Forghani, Johanna Leifland and Louise Austin have been promoted “in recognition of their hard work, success and progress”.

Sanofi-aventis has added Dr Richard Klausner as chairman of the Strategic Development and Scientific Advisory Council, effective March 1, 2011. He will act as special scientific and strategic adviser to chief executive Christopher A Viehbacher.

Dr Richard Klausner

Lawson MacartneyMario Saltarelli

Shire has appointed two senior R&D executives to its speciality pharmaceuticals business: Lawson Macartney (left) has been selected as senior vice president of the emerging business unit and Mario Saltarelli (right) has been named senior vice president of clinical development and medical affairs. Macartney is responsible for the early pipeline and development efforts of Shire's speciality pharmaceuticals business, which is centred on attention deficit hyperactivity disorder and gastrointestinal diseases. Meanwhile Saltarelli will provide overall scientific and professional leadership, as well as clinical and medical strategies for Shire's global drug development programmes. He has previously worked at Abbott Laboratories and Pfizer Global Research and Development.

Lundbeck chairman Per Wold-Olsen has resigned from the company's board. Wold-Olsen, who has been chairman since 2007, said he was stepping down because of commitments to other board, private equity fund duties and consulting assignments that could lead to conflicts of interest.

Per Wold-Olsen

LifeLife Healthcare Communications has appointed three new employees and extended its Digital department. Marcella Hodgson joins the company as office manager, Stuart Gordon has been appointed as production and design manager, Sandra Vickery adds her expertise as a digital designer, and Sophie Gibbons returns from maternity leave to resume her role in the expanded production department.

GSK has also appointed Judy Lewent and Stacey Cartwright as non-executive directors. They will become members of GSK's audit and risk committee. Lewent is the former executive vice president and chief financial officer of Merck, while Cartwright is executive vice president and chief financial officer of Burberry Group.

Professor Sir Michael Rawlins has received a special exemption to continue to serve as chairman of the UK's costs regulator, the National Institute for Health and Clinical Excellence (NICE). In ordinary circumstances, appointments to chair UK public bodies are restricted to 10 years. However, Rawlins has been granted the special exemption, his second, to serve as chairman for another year while NICE transitions into the National Institute for Health and Care Excellence.

Dr Greg Plowman has been chosen to lead Eli Lilly's oncology research efforts as the vice president, oncology research and senior vice president of ImClone Systems research. Plowman will oversee the oncology research efforts of both Lilly and its subsidiary, ImClone. Plowman will be based at ImClone's research centre at the Alexandria Center for Life Science, New York City, US.

Allergan's chairman and chief executive David Pyott has been re-appointed to the role of company president. Pyott replaces the departing F Michael Ball, who becomes chief executive of Hospira. The move will see Pyott once again take up a role he originally filled from 1998 until 2006.

Oxford BioMedica has appointed James Christie to the newly created role of head of manufacturing, following its acquisition of a manufacturing facility based in Oxford, UK from RecipharmCobra Biologics. Christie, a senior biopharmaceutical executive with more than 30 years of experience, has worked for BTG, GSK, Celltech Group, Centocor and Therapeutic Antibodies.

Aegate has selected Sir David Cooksey as chairman of its board. Cooksey has served on the boards of the Audit Commission, as senior independent director of the Bank of England and as a governor of the Wellcome Trust.

Donald Patton, head of Abbott Laboratories' US pharmaceutical business, is to retire and the medical-products company is merging its American and international businesses into one. Patton has been senior vice president of the company since January 2010.

Bruno Delie has been appointed as an executive vice president business development of Ethypharm. He is also a member of the management board. Delie has held positions at Parke Davis, Roquette and Prographarm Group. He joined Ethypharm as business development director Europe in 2000 and became vice president of sales and marketing in 2004.

IDEA Pharma has appointed Michael Morgan-Curran to its strategic delivery team, tasked with shaping and leading new approaches to help clients make better decisions for products across a variety of therapeutic areas. Morgan-Curran has 22 years' experience working in the pharmaceutical and consultancy industry.

Joao Almeida Lopes has been re-elected president of the Portuguese Association of the Pharmaceutical Industry, Apifarma. Lopes is head of the Portuguese company, Laboratorio Medinfar. Members elected vice president were Joao Barroca of Bayer Portugal and Eduardo Pinto Leite of GlaxoSmithKline Produtos Farmaceuticos. Antonio Chaves Costa of Tecnifar Farmaceutica was elected treasurer.

UK-based Clinigen has selected Mark Corbett as its global strategic planning director. He joined from Idis where he was head of European business development and a global account director. Corbett will be responsible for new business generation and strategic development of the Clinigen service offered to biotechnology and pharmaceutical companies.

Jo Jarvis has joined the Fishawack UK team as director, stakeholder strategies. Jo brings a wealth of experience to the group, having worked at Wyeth for more than 20 years, most recently as head of advocacy.

International law firm Simmons & Simmons has expanded its life sciences practice in Paris with the appointment of dispute resolution partner Michèle Anahory. Michèle specialises in the pharmaceutical and healthcare sectors, with a particular focus on public and private healthcare companies.

Former co-founder and design director of Life Healthcare Communications, Ben Blackmore has set up a new mixed media agency, b more creative, based in Basingstoke, UK.  The agency will focus on bringing fresh, exciting and new ideas to the pharmaceutical industry with a special emphasis on new media and digital solutions.

OPEN Health has appointed Margot Rozga as associate partner. Her primary responsibility will be to build the medical communications business alongside Sandy Royden.

Related links

FAQ: How do I get my move listed


Subscribe to our email news alerts

Featured jobs


Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....